← Back to Clinical Trials
Recruiting NCT04425421

NCT04425421 Recommendations for the Treatment of Children With Burkitt's Lymphoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04425421
Status Recruiting
Phase
Sponsor French Africa Pediatric Oncology Group
Condition Burkitt Lymphoma
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2020-11-01
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 18 Years
Study Type OBSERVATIONAL
Interventions
OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2020-11-01 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

Eligibility Criteria

Inclusion Criteria: Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment. \- Exclusion Criteria: Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.

Contact & Investigator

Central Contact

Chantal Ms BOUDA, Dr.

✉ cgbouda@yahoo.fr

📞 00(226)70 10 01 30

Frequently Asked Questions

Who can join the NCT04425421 clinical trial?

This trial is open to participants of all sexes, up to 18 Years, studying Burkitt Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04425421 currently recruiting?

Yes, NCT04425421 is actively recruiting participants. Contact the research team at cgbouda@yahoo.fr for enrollment information.

Where is the NCT04425421 trial being conducted?

This trial is being conducted at Ouagadougou, Burkina Faso, Abidjan, Côte d’Ivoire, Kinshasa, Democratic Republic of the Congo, Lubumbashi, Democratic Republic of the Congo and 3 additional locations.

Who is sponsoring the NCT04425421 clinical trial?

NCT04425421 is sponsored by French Africa Pediatric Oncology Group. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology